We are Sorry, This Page doesn't Exist
Why BioCryst’s HAE Treatment Failed to Impress
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients......»»
How Intercept Pharma Shatters Expectations With Its Liver Fibrosis Treatment
Intercept Pharmaceuticals shares jumped on Tuesday after the firm announced results for its Phase 3 Regenerate study of obeticholic acid in patients with liver fibrosis due to nonalcoholic........»»
Raleigh pharma to study coronavirus treatment on patients in U.S.
A Triangle drugmaker that's seen positive results with its Covid-19 treatment internationally can now start treating patients in the U.S. Raleigh's RedHill Biopharma (Nasdaq: RDHL) has received approval from the U.S. Food and Drug Administration .....»»
Exclusive: Trial of Gilead"s potential coronavirus treatment running ahead of schedule, researcher says
A key U.S. government trial of Gilead Sciences Inc's experimental coronavirus treatment may yield results as early as mid-May, according to the study's lead investigator, after doctors clamored to enroll their patients in the study......»»
Why This PNH Study Could Set the Standard for Treatment
Apellis Pharmaceuticals shares jumped on Tuesday after the firm announced positive results from its late stage study in adults with paroxysmal nocturnal hemoglobinuria (PNH). Specifically, the data........»»
Xeris Pharma stock rallies more than 20% on study results
Xeris Pharmaceuticals Inc. shares rallied in the extended session Monday after the drug maker said its diabetes treatment showed positive results in a .....»»
Hepion Pharmaceuticals" stock rockets after upbeat results of preclinical study of liver cirrhosis treatment
Shares of Hepion Pharm.....»»
Reata Pharma kidney drug meets study goals, stock halted
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study. Reata shares were flat, following a .....»»
Amgen"s early-stage study of cancer treatment had "adverse events" in nearly half of its patients
Amgen Inc. said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment .....»»
Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
AZEDRA® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat Patients Phase 2 Trial of 1095 Initiated with Enrollment to Begin 2Q.....»»
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results
- Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-i.....»»
Merck"s Keytruda no better than chemo as a first-line treatment for gastric cancer, according to Phase 3 study results
Merck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of th.....»»
Supernus" ADHD Candidate Positive in 4th Phase III Study
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder. Wan.....»»
Madrigal preparing for late-stage testing of experimental NASH treatment
Madrigal Pharmaceuticals presented "statistically significant" results from midstage testing of its lead new drug candidate for NASH during Monday's annual meeting of the American Association for the Study of Liver Diseases in San Francisco. The Conshoh.....»»
Vanda Pharma Nails Midstage Gastroparesis Study
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis......»»
Supernus Gets Crushed Despite Positive ADHD Study Results
Supernus Pharmaceuticals shares dipped on Thursday despite the firm posted positive results from two of its late-stage studies in children for the treatment of attention deficit hyperactivity........»»
Ra Pharmaceuticals Delivers on Midstage Muscle Study
Ra Pharmaceuticals shares jumped on Monday after the company announced positive mid-stage results for the treatment of generalized myasthenia gravis......»»
Where Does Aptinyx Go Next After Disappointing Midstage Results for Pain Treatment?
Aptinyx shares were absolutely crushed on Wednesday after the firm reported midstage results from its clinical study in patients with painful diabetic peripheral neuropathy......»»
Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data
Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with lo.....»»
Johnson & Johnson-Partnered Addex Therapeutics" Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care. read more.....»»